Menu Search
Equities

Amgen Inc

AMGN:NSQ

Amgen Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)289.70
  • Today's Change1.83 / 0.64%
  • Shares traded672.79k
  • 1 Year change+10.23%
  • Beta0.5680
Data delayed at least 15 minutes, as of Nov 21 2024 16:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 15-Nov-24
Select bar for recommendation details.
Recommendations15-Nov-24
Buy7
Outperform9
Hold16
Sell1
Strong Sell1

Share price forecast in USD

The 27 analysts offering 12 month price targets for Amgen Inc have a median target of 344.00, with a high estimate of 405.00 and a low estimate of 200.00. The median estimate represents a 19.50% increase from the last price of 287.87.
High40.7%405.00
Med19.5%344.00
Low-30.5%200.00

Dividends in USD

In 2023, Amgen Inc reported a dividend of 8.52 USD, which represents a 9.79% increase over last year. The 14 analysts covering the company expect dividends of 9.09 USD for the upcoming fiscal year, an increase of 6.69%.
Div growth (TTM)9.79%
More ▼

Earnings history & estimates in USD

On Oct 30, 2024, Amgen Inc reported 3rd quarter 2024 earnings of 5.58 per share. This result exceeded the 5.11 consensus of the 21 analysts covering the company and exceeded last year's 3rd quarter results by 12.50%.
The next earnings announcement is expected on Feb 04, 2025.
Average growth rate+4.20%
Amgen Inc reported annual 2023 earnings of 18.65 per share on Feb 06, 2024.
Average growth rate+5.97%
More ▼

Revenue history & estimates in USD

Amgen Inc. had 3rd quarter 2024 revenues of 8.50bn. This missed the 8.52bn consensus estimate of the 21 analysts following the company. This was 39.28% above the prior year's 3rd quarter results.
Average growth rate+5.90%
Amgen Inc. had revenues for the full year 2023 of 28.19bn. This was 7.09% above the prior year's results.
Average growth rate+4.42%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.